We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Drug Causing Severe Side Effects Is Withdrawn

By HospiMedica staff writers
Posted on 15 Dec 2000
A prescription medication approved to treat irritable bowel syndrome (IBS) in women has been voluntarily withdrawn from the market by the manufacturer at the request of the U.S. More...
Food and Drug Administration (FDA). The drug, alosetron hydrochloride (Lotronex), is the product of Glaxo Wellcome (London, UK).

The company's action followed an analysis by the U.S. Food and Drug Administration (FDA) of reports of serious side effects since the drug's approval in February, including the deaths of five patients. Other side effects that were reported included 49 cases of ischemic colitis and 21 cases of severe constipation. In all, 34 cases resulted in hospitalization.

Following its analysis, the FDA met with Glaxo Wellcome to consider a number of marketing options, including restricting distribution of the drug or market withdrawal. At the conclusion of the meeting, Glaxo informed the FDA that it would voluntarily withdraw the drug. In the meantime, the FDA is advising patients taking the drug to contact their healthcare providers in order to discuss alternative treatments.



Related Links:
FDA
Glaxo Wellcome

New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Surgical Dressing
ALLEVYN Ag+ SURGICAL
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Allevion Medical receives FDA Clearance for Vantage, introducing a fully disposable approach to minimally invasive spinal decompression (photo courtesy of Allevion Medical)

Single-Use System Enables Minimally Invasive Decompression for Lumbar Spinal Stenosis

Lumbar spinal stenosis is frequently driven by hypertrophic bone that narrows the canal and produces pain. Conventional decompression often relies on larger incisions and bulky retractors, adding time,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.